#	Pagina
attuale pagina	/open-h2020/projects/217047/index.html
-1	/open-h2020/projects/214943/index.html
-2	/open-fp7/projects/104703/index.html
-3	/open-h2020/projects/223404/index.html
-4	/open-h2020/per-topic/fets/list/index.html
-5	/open-fp7/projects/91873/index.html
-6	/open-h2020/per-topic/inferential/list/index.html
-7	/open-h2020/projects/196835/index.html
-8	/open-h2020/projects/224925/index.html
-9	/open-fp7/projects/101858/index.html
-10	/open-h2020/projects/203530/index.html

Opendata, web and dolomites

AuriGen SIGNED

Next Generation Left Atrial Appendage Implant to Treat Persistent Atrial Fibrillation

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

AuriGen project word cloud

Explore the words cloud of the AuriGen project. It provides you a very rough idea of what is the project "AuriGen" about.

5bn device first commercial filter occlusion services health isolation time patients million shut hours destroys electrically approximately healthcare international pulses rates muscle arrhythmia enter mechanically france ce causing uk tissue af fitting heartbeat classified abnormal electrical market invasive paf risk distributors opportunity wasted entering markets shot treatment implants stroke fibrillation financially blood 30 doubled complete atrial doubles surgical treating human contraction fit therapy caused clinical cardiac amounting works expand too billion italy launch redo isolates prevent left persistent clots opening approval procedure minimally laa flow permanently tier stream surgery 72 germany irregular appendage 13 specialist implant heart incapable least

Project "AuriGen" data sheet

The following table provides information about the project.

Coordinator	AURIGEN MEDICAL LIMITED Organization address address: 18 CHURCHWELL SQUARE city: DUBLIN postcode: DUBLIN 13 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Project website	http://www.aurigenmedical.com
Total cost	3˙503˙093 €
EC max contribution	2˙452˙165 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2018
Duration (year-month-day)	from 2018-07-01 to 2020-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	AURIGEN MEDICAL LIMITED AURIGEN MEDICAL LIMITED Organization address address: 18 CHURCHWELL SQUARE city: DUBLIN postcode: DUBLIN 13 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN)	coordinator	2˙452˙165.00

Map

Project objective

Atrial Fibrillation (AF) is an irregular heartbeat that can lead to blood clots, high risk of stroke and heart failure. AF is caused by abnormal electrical activity in the heart. There are 10.7 million AF patients across Europe and the US, 3.6 million are classified as having Persistent AF (PAF). Surgical treatment for AF is a minimally invasive electrical therapy which destroys heart tissue causing the abnormal electrical pulses. For PAF patients, this works only 30% of the time. Approximately 72% of PAF patients require at least one redo procedure, amounting to €13.5 billion in wasted healthcare costs. Success rates are doubled if electrical activity in a part of the heart “the Left Atrial Appendage” (LAA), is shut down. But this increases stroke risk from blood clots as the LAA is now incapable of muscle contraction to maintain blood flow. LAA implants, “occlusion devices” fit across the opening of the LAA to filter the blood and prevent clots from entering the blood stream. However, fitting an occlusion device during the same procedure as LAA electrical isolation doubles procedure time (to 7 hours) making it non-financially viable for health services and too high risk for patients.

We have developed a unique, minimally invasive cardiac implant which permanently electrically and mechanically isolates the LAA in a one-shot procedure: treating both the stroke and arrhythmia risk associated with PAF with no increase in surgery time. EU and US PAF represents a $5bn/yr market opportunity. We will enter the market directly in our target Tier 1 European markets (Germany, France, Italy and UK). We will scale using specialist distributors to expand into further European, US and other international markets.

In this Phase 2 we will complete the technical, pre-clinical and first in human clinical studies required to achieve CE approval in Europe as well as market development work for commercial launch.

Deliverables

List of deliverables.
Sales Director Appointed	Other	2019-11-25 12:36:59
Operations Director Appointed	Other	2019-11-25 12:36:58

Take a look to the deliverables list in detail: detailed list of AuriGen deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AURIGEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AURIGEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat